Pembrolizumab vs Tofacitinib Citrate
Pembrolizumab vs Tofacitinib Citrate: Overview
This comparison examines the pharmacological differences between Pembrolizumab and Tofacitinib Citrate.
Mechanism of Action
Pembrolizumab: Anti-PD-1 monoclonal antibody restoring anti-tumor immunity.
Pharmacokinetics
Half-life: Pembrolizumab — 26 days.
Chemical Properties
Type: Pembrolizumab — Antibody; Tofacitinib Citrate — Small molecule.